A new report by Mizuho analyst Peter Lawson focuses on biotech stocks with major catalysts on the way between now and the end of 2016. Perhaps more than any other sector, biotech stocks move based on major events, and here is a breakdown of what biotech traders should be watching.

1. Clovis Oncology Inc CLVS 0.75%: Clovis should be providing an update on rociletinib at the World Lung conference September 6-9, rociletinib could gain FDA approval and launch commercially shortly thereafter and lucitanib Phase II breast data should be coming at SABCS.

2. Epizyme Inc EPZM 1.14%: Epizyme catalysts include tazemetostat Phase I solid tumor data at ECC in September, and NHL data and updates on strategy and pinometostat combo usage by year-end.

3. Kite Pharma Inc KITE 1.49%: Kite should be providing Phase I data on KTE-C19 at ASH in December and could also provide updates on solid tumors as well as initiate MCL, ALL and CLL trials by the end of the year.

4. Merrimack Pharmaceuticals Inc MACK 0.95%: Merrimack has an October 24 PDUFA date for MM-398, but shareholders should also be watching…

Click here to continue reading

Want to learn more about how to profit off the stock market? Or maybe you just want to be able to look sophisticated in front of your coworkers when they ask you what you are reading on your Kindle, and you’d prefer to tell them “Oh, I’m just reading a book about stock market analysis,” rather than the usual “Oh, I’m just looking at pics of my ex-girlfriend on Facebook.” For these reasons and more, check out my book, Beating Wall Street with Common Sense. I don’t have a degree in finance; I have a degree in neuroscience. You don’t have to predict what stocks will do if you can predict what traders will do and be one step ahead of them. I made a 400% return in the stock market over five years using only basic principles of psychology and common sense. Beating Wall Street with Common Sense is now available on Amazon, and tradingcommonsense.com is always available on your local internet!